Logo Image
|Videos|September 15, 2020

Investigational Treatment Shows Potential to Supress Memory Loss

Aaron Burstein, PharmD, shares details from a scientific presentation at the Alzheimer's Association International Conference.

MENTAL HEALTH MINUTE

Aaron Burstein, PharmD, senior vice president of vTv Therapeutics, shares the history and current status of development of azeliragon for the treatment of dementia and diabetes, including results recently presented at the 2020 Alzheimer's Association International Conference.

Related Content

Latest CME

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care
Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

View more
Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia
Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

View more
Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder
Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

View more